Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment
  1. Outputs

Precision pathways: optimising amyloid PET for sustainable Alzheimer’s disease care

Academic Article
Publication Date:
2026
Short description:
Precision pathways: optimising amyloid PET for sustainable Alzheimer’s disease care / Morbelli, S.D., Bozzali, M., Cagnin, A., Cecchin, D., Chiti, A., Filippi, M.. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - 273:6(2026). [10.1007/s00415-026-13874-2]
abstract:
The approval of anti-amyloid therapies has reshaped Alzheimer’s disease from a clinically defined syndrome to a biologically confirmed and treatment-oriented condition. This transition places biomarkers, particularly amyloid positron emission tomography (Aβ-PET), at the centre of diagnostic precision, patient selection, safety governance, and therapeutic monitoring. Aβ-PET provides high specificity for confirming cerebral amyloid pathology, especially in cases with discordant or inconclusive fluid biomarkers, and supports staging through semi-quantitative assessment using standardised Centiloid metrics. In patients considered for anti-amyloid therapies, baseline Aβ-PET refines eligibility and risk–benefit profiling when integrated with MRI and APOE genotyping. During treatment, longitudinal Aβ-PET enables objective assessment of pharmacodynamic target engagement and treatment-related amyloid clearance, supporting response-adapted strategies and, in selected cases, therapy discontinuation. Beyond its clinical role, Aβ-PET has strategic organisational and economic implications. Its value is maximised when embedded within structured, stepwise diagnostic pathways that use scalable fluid biomarkers for triage and reserve Aβ-PET for high-impact decisions. However, implementation is challenged by regional heterogeneity, capacity constraints, and limited harmonisation across centres. Coordinated hub-and-spoke models, quantitative standardisation, and prospective registry-based data collection are essential to ensure the equitable and sustainable integration of anti-amyloid therapies into clinical practice. Aβ-PET has evolved from a confirmatory diagnostic tool to a strategic instrument that enables biologically driven, outcome-oriented care for patients with Alzheimer’s disease.
Iris type:
1.1.1 Articolo in rivista - Review
List of contributors:
Morbelli, S. D.; Bozzali, M.; Cagnin, A.; Cecchin, D.; Chiti, A.; Filippi, M.
Authors of the University:
CHITI ARTURO
FILIPPI MASSIMO
Handle:
https://iris.unisr.it/handle/20.500.11768/204676
Full Text:
https://iris.unisr.it//retrieve/handle/20.500.11768/204676/360422/unpaywall-bitstream--662978527.pdf
Published in:
JOURNAL OF NEUROLOGY
Journal
  • Overview

Overview

URL

https://link.springer.com/article/10.1007/s00415-026-13874-2
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.11.1.0